Sujata Patil, PhD
Associate Staff
Joint Appointment in Taussig Cancer Institute
Email: [email protected]
Location: Cleveland Clinic Main Campus
Research
The Sujata Patil research program develops and uses statistical methods and designs to understand the science and biology of cancer.
Biography
I joined the Cleveland Clinic as Associate Staff Biostatistician in the Department of Quantitative Health Sciences and as Section Head of Cancer Biostatistics in January of 2021. Prior to joining Cleveland Clinic, I was a faculty biostatistician at Memorial Sloan Kettering Cancer Center in New York City for 15 years. I received my PhD in Biostatistics from the University of Michigan in 2005 with a dissertation that focussed on Bayesian methods to analyze longitudinal trajectories and their outcomes.
Collaborative research, in particular study design and analysis, has been at the foundation of my work. These collaborations have principally been with breast, genitourinary and colorectal oncologists, surgeons and pathologists as well as health outcomes investigators. Beyond this work, I have methodological research interests in study design, survival data analysis, and analysis with missing data. Two areas of ongoing methodological work are in 1) tests to compare two or more different cumulative risk distributions and 2) missing cause of death in competing risks analysis. In addition to the collaborative and methodological work, I have also devoted time to the education. I have given didactic statistics lectures targeted to clinical fellows, junior scientists and graduate students locally and regionally on lecture topics that have included Phase III trial designs, predictive modeling and survival analysis.
Education & Professional Highlights
Undergraduate
Northwestern University; BA Mathematics, minor Slavic Studies
Graduate
Yale University; MPH Biostatistics Concentration
University of Michigan; MS, PhD Biostatistics
Work Experience
Faculty Biostatistician at Memorial Sloan Kettering Cancer Center; 2006-2020
Associate Staff Biostatistician at the Cleveland Clinic; 2021-
Research
Cancer Biostatistics Section
The primary activity of the Cancer Biostatistics Section is to engage in short and long-term collaborations with cancer physicians and scientists. In particular, we provide support in study design (sample size, power, and endpoint choice), statistical analysis (appropriate methods) and grant/protocol writing. An individual biostatistician is often involved as a member of a scientific team (such as a disease area, or a research program), and participates in multiple research projects. We also participate in shorter-term consulting with investigators, and help support abstract and small grant submissions. In line with the primary objectives of the Case Comprehensive Cancer Center, we support protocol submission and review, as well as fellow and medical student training. Professional staff have also pursued their own methodological statistics research via publications and talks throughout the local, national and international academic community.
Supplementing this work, our team members have served as editorial staff or reviewers for journals such as JCO, R Journal, JAMA, Cancer, and the Journal of Urology among others. We have served on protocol, as well as local and national grant and abstract review committees.
Our Team
Selected Publications
View publications for Sujata Patil, PhD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Selected Publications
- Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, Verheij FS, Omer DM, Lee M, Dunne RF, Marcet J, Cataldo P, Polite B, Herzig DO, Liska D, Oommen S, Friel CM, Ternent C, Coveler AL, Hunt S, Gregory A, Varma MG, Bello BL, Carmichael JC, Krauss J, Gleisner A, Paty PB, Weiser MR, Nash GM, Pappou E, Guillem JG, Temple L, Wei IH, Widmar M, Lin S, Segal NH, Cercek A, Yaeger R, Smith JJ, Goodman KA, Wu AJ, Saltz LB. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022 Apr 28.
- Kim JK, Marco MR, Roxburgh CSD, Chen CT, Cercek A, Strombom P, Temple LKF, Nash GM, Guillem JG, Paty PB, Yaeger R, Stadler ZK, Gonen M, Segal NH, Reidy DL, Varghese A, Shia J, Vakiani E, Wu AJ, Romesser PB, Crane CH, Gollub MJ, Saltz L, Smith JJ, Weiser MR, Patil S*, Garcia-Aguilar J*. Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. Oncologist. 2022 Mar 12.
- Patil S, Satagopan J. Building and teaching a statistics curriculum for post-doctoral biomedical scientists at a free-standing cancer center. Chance Magazine 35:1, 56-64, Feb 2022
- Kotecha RR, Hsu DJ, Lee CH, Patil S, Voss MH. In silico modeling of combination systemic therapy for advanced renal cell carcinoma J Immunother Cancer. 2021 Dec;9(12):e004059.
- Zabor EC, Reddy CA, Tendulkar RD, Patil S. Logistic regression in clinical studies. Int. J. Radiat. Oncol. Biol. Phys. 2021
- Funt SA*, Patil S*, Feldman DR, Motzer RJ, Bajorin DF, Sheinfeld J, Tickoo SK,Reuter VE, Bosl GJ. Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. J Clin Oncol. 2019 2019 Sep 10;37(26):2329-2337.
- Blinder VS, Eberle CE, Tran C, Bao T, Malik M, Jung G, Hwang C, Kampel L, Patil S, Gany FMJ. Use of patient-reported controls for secular trends to study disparities in cancer-related job loss. Cancer Surviv. 2020 Oct 26.
- Blinder VS, Patil S, Finik J, Makower D, Muppidi M, Lichtenthal WG, Parker PA, Claros M, Suarez J, Narang B, Gany F. An interactive mobile application versus an educational booklet to promote job retention in women undergoing adjuvant chemotherapy for breast cancer: a randomized controlled trial. Trials. 2022 Oct 3;23(1):840.
- Patil S, Ishill N, Deluca J, Motzer RJ. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. Cancer. 2010 Jan 15;116(2):347-54.
- Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ. Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib versus interferon-alfa. Br J Cancer. 2012 May 8;106(10):1587-90.
*contributed equally to this work